Chromosome..."Terms of the agreement( i.e. in 2015) include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens."
With the anticipated large volume of Vaskapa sales in China, the sales base volume should reach $150 million briskly.
As J.T. said..."Vascepa is a volume play...not a price play."
News 
Market Data 
Discover 
AI
